Ajay K. Singh discussed his findings on daprodustat dosing and utilization of finerenone. Could urinary podocyte stress biomarker be a surrogate marker of podocyte injury in diabetic kidney disease (DKD)? Medicare Part D spending on GLP-1 drugs has soared to $5.7 billion, straining Medicare spending. Current practice guidelines do not address dietary management specific to diabetic kidney disease (DKD). The most common primary renal disease in patients initiating renal replacement therapy is diabetes. Several classes of glucose-lowering drugs have been shown to have kidney benefits in patients with type 2 diabetes. The most common concomitant medication classes were antihypertensives (95%), antihyperglycemic (81%), and statins (79%). Preliminary evidence has demonstrated preservation of kidney function as measured by eGFR compared with baseline. There was a five-fold higher risk of hyperkalemia with use of a steroidal MRA plus an ACEi or ARB. Assessing the early impact of risk categorization on management of patients with DKD. Gaps in care in treating proteinuria in patients with DKD. In the population of patients with chronic kidney disease (CKD), particularly those with diabetes as the underlying ... In patients with type 2 diabetes, ectopic fat is a major pathogenic factor. According to Niels Sondergaard Heinrich, MD, ... Nonalbuminuric diabetic kidney disease (DKD) has become the prevailing phenotype of DKD. Qiao Jin, MSc, and colleagues, ... According to Mukoso N. Ozieh, MD, and Leonard E. Egede, MD, MS, of the Medical College of Wisconsin, behavioral factors, ... FIDELITY, a prespecified pooled analysis of results from the phase 3 FIDELIO-DKD and FIGARO-DKD trials, demonstrated ... Patient education is a component of prevention of progression of kidney disease. Paul Flynn and colleagues at SUNY ... Clinical trials in nephrology are enriched for patients with micro- or macroalbuminuria to enroll patients at risk of ... Among obese patients with type 2 diabetes, hyperfiltration is a risk factor for accelerated decline in glomerular ... Worldwide, the prevalence of end-stage kidney disease (ESKD) is increasing; the leading cause of ESKD is diabetes. The ...